Claims for Patent: 7,713,735

Summary for Patent: 7,713,735

Title:	Gene silencing
Abstract:	The present invention relates to unique strategies and constructs for producing a nucleic acid product that downregulates or prevents expression of a desired target polynucleotide.
Inventor(s):	Rommens; Caius (Boise, ID), Yan; Hua (Boise, ID), Bougri; Oleg (Boise, ID), Swords; Kathy M. M. (Boise, ID)
Assignee:	J.R. Simplot Company (Boise, ID)
Application Number:	11/233,483
Patent Claims:	1. A construct, comprising an expression cassette for reducing gene expression in a plant comprising (i) a polynucleotide and (ii) an inverted repeat of the polynucleotide, which are positioned in between, and operably linked to, two promoters that are each functional in plants, wherein (a) the polynucleotide and its inverted repeat are fully identical in sequence over at least 23 nucleotides, (b) the direction of transcription is from one promoter toward the other promoter, and (c) neither the polynucleotide nor its inverted repeat is operably linked to a terminator. 2. The construct of claim 1, wherein the polynucleotide of (i) shares sequence identity with a regulatory element, an exon, an intron, the 5'-untranslated region, or the 3'-untranslated region of the endogenous plant gene. 3. The construct of claim 2, wherein the target gene is a COMT gene involved in lignin biosynthesis, a CCOMT gene involved in lignin biosynthesis, any other gene involved in lignin biosynthesis, an R1 gene involved in starch phosphorylation, a phosphorylase gene involved in starch phosphorylation, a PPO gene involved in oxidation of polyphenols, a polygalacturonase gene involved in pectin degradation, a gene involved in the production of allergens, or a gene involved in fatty acid biosynthesis. 4. The construct of claim 1, wherein the expression cassette is located between transfer-DNA border sequences of a plasmid that is suitable for bacterium-mediated plant transformation, wherein the bacterium is a strain of Agrobacterium, Rhizobium, or Phyllobacterium. 5. The construct of claim 1, further comprising a spacer polynucleotide positioned between the polynucleotide and the inverted repeat wherein the spacer polynucleotide is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, or more than 500 nucleotides long. 6. The construct of claim 1, wherein each promoter is selected from the group consisting of a constitutive promoter, a tissue-specific promoter, or an inducible promoter and wherein the second promoter is a constitutive promoter, a near-constitutive promoter, a tissue-specific promoter, or an inducible promoter. 7. The construct of claim 3, wherein the gene involved in fatty acid biosynthesis is FAD2.

Details for Patent 7,713,735

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2024-09-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2024-09-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2024-09-24